<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069848</url>
  </required_header>
  <id_info>
    <org_study_id>Avedro T4</org_study_id>
    <nct_id>NCT01069848</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the Vedera KXS for Treatment of Keratoconus</brief_title>
  <official_title>Feasibility Study of the Vedera KXS for Treatment of Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to evaluate the feasibility, safety and efficacy of&#xD;
      the Vedera KXS for the reduction or elimination of myopia and astigmatism in patients with&#xD;
      keratoconus, who are no longer able to achieve adequate vision with their contact lenses or&#xD;
      glasses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction in Kmax (by keratometry) of &gt;1 D</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Vedera KXS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vedera KXS</intervention_name>
    <description>One treatment session with Vedera KXS</description>
    <arm_group_label>Vedera KXS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 14 years of age or older&#xD;
&#xD;
          2. Presence of central or inferior steepening on the Pentacam map&#xD;
&#xD;
          3. Axial topography consistent with keratoconus&#xD;
&#xD;
          4. I-S ratio &gt; 1.5 on the Pentacam map or topography map&#xD;
&#xD;
          5. BSCVA worse than 20/20 (&lt;53 letters on ETDRS chart)&#xD;
&#xD;
          6. Contact Lens Wearers Only: Removal of contact lenses for the required period of time&#xD;
             prior to the screening refraction&#xD;
&#xD;
          7. Signed written informed consent&#xD;
&#xD;
          8. Willingness and ability to comply with schedule for follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Eyes classified as either normal or atypical normal on the keratoconus severity&#xD;
             grading scheme.&#xD;
&#xD;
          2. A history of previous corneal surgery or the insertion of Intacs in the eye(s) to be&#xD;
             treated.&#xD;
&#xD;
          3. Corneal pachymetry &lt;400 microns at diameter to be treated.&#xD;
&#xD;
          4. Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example:&#xD;
&#xD;
               1. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis,&#xD;
                  recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)&#xD;
&#xD;
               2. Clinically significant corneal scarring in the treatment zone that is not related&#xD;
                  to keratoconus or, in the investigator's opinion, will interfere with the&#xD;
                  treatment.&#xD;
&#xD;
          5. A history of chemical injury or delayed epithelial healing in the eye(s) to be&#xD;
             treated.&#xD;
&#xD;
          6. Diagnosed with autoimmune disease, systemic connective tissue diseases or atopic&#xD;
             syndrome, diabetes mellitus, or taking systemic medications likely to affect wound&#xD;
             healing.&#xD;
&#xD;
          7. Women who are pregnant or nursing or who plan to become pregnant over the course of&#xD;
             their participation in this investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beyoglu Eye Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

